Last 45 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
NanoVibronix, Inc.'s quarterly P/E stands at 1.3x.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.14 | 1.34 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.20 | 0.95 | 2.27 | 2.24 | 11.60 | 12.54 | 6.56 | 6.75 | 5.50 | 20.36 | 53.33 | 44.02 | — |
| — | -92.5% | -65.3% | -66.7% | +110.9% | -38.4% | -87.7% | -84.7% | — | -94.4% | -46.7% | -86.6% | — | |
| P/B Ratio | 0.82 | 0.06 | 0.11 | 0.26 | 32.85 | 10.08 | 7.55 | 7.09 | 6.49 | 7.95 | 53.84 | 28.29 | 24.34 |
| — | -99.4% | -98.5% | -96.4% | +406.1% | +26.7% | -86.0% | -74.9% | -73.3% | -82.3% | +14.7% | -58.3% | -48.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | -0.44 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
NanoVibronix, Inc.'s operating margin was -311.2% in Q3 2025, up 493.6 pp QoQ and down 53.2 pp YoY. The trailing four-quarter average of -401.3% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 26.0% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.0% | 26.2% | -7.1% | 36.0% | 63.7% | 35.4% | 52.4% | 72.1% | 62.6% | 76.2% | 73.5% | 66.4% | 294.1% |
| — | -26.0% | -113.5% | -50.1% | +1.8% | -53.6% | -28.7% | +8.6% | -78.7% | -7.6% | +26.8% | +70.3% | +786.9% | |
| Operating Margin | -140.0% | -311.2% | -804.9% | -180.7% | -308.6% | -258.0% | -82.5% | -61.7% | -59.6% | -146.3% | -343.2% | -298.0% | 1674.5% |
| — | -20.6% | -875.6% | -193.0% | -417.3% | -76.3% | +76.0% | +79.3% | -103.6% | +84.6% | -31.3% | +27.1% | +617.0% | |
| Net Margin | -144.8% | 70.6% | -31.6% | -243.4% | -322.3% | -265.4% | -84.2% | -63.8% | -69.1% | -158.7% | -365.3% | -309.9% | 2018.6% |
| — | +126.6% | +62.5% | -281.3% | -366.6% | -67.2% | +76.9% | +79.4% | -103.4% | +83.9% | -36.1% | +25.5% | +732.4% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -160.6% | 1.2% | -0.4% | -13.7% | -114.5% | -42.4% | -21.7% | -15.7% | -18.7% | -24.8% | -63.8% | -40.4% | -64.5% |
| — | +102.9% | +98.1% | +12.4% | -511.2% | -70.5% | +66.0% | +61.1% | +70.9% | +5.2% | -130.1% | -106.3% | -95.8% | |
| ROA | -71.9% | 1.0% | -0.3% | -10.5% | -34.4% | -19.2% | -11.5% | -9.1% | -11.6% | -13.0% | -24.9% | -20.5% | -37.1% |
| — | +105.0% | +97.2% | -14.8% | -197.2% | -48.0% | +53.6% | +55.6% | +68.8% | +20.1% | -35.6% | -47.6% | -37.3% | |
| ROIC | -766.5% | -4.4% | -7.7% | -7.1% | -300.4% | -97.2% | -58.8% | -52.5% | -64.5% | -53.7% | -89.3% | -117.5% | -141.5% |
| — | +95.5% | +86.9% | +86.4% | -365.6% | -80.9% | +34.1% | +55.3% | +54.4% | +44.5% | +79.1% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 50.5% YoY to 0.86x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.19 | 0.07 | 0.05 | 0.11 | 0.19 | 0.07 | 0.05 | 0.03 | 0.00 | 0.00 | 0.03 | 0.02 | 0.03 |
| — | +10.9% | +12.1% | +249.7% | +14653.4% | +1561.5% | +47.4% | +25.7% | -95.0% | -54.4% | +297.8% | +198.5% | +222.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.22 | 0.86 | 1.05 | 0.47 | 1.22 | 1.74 | 2.11 | 2.45 | 2.64 | 3.00 | 1.52 | 1.99 | 2.42 |
| — | -50.5% | -50.0% | -80.8% | -53.7% | -42.1% | +38.2% | +22.8% | +9.1% | +3.0% | -50.4% | -45.8% | -44.8% | |
| Quick Ratio | 0.42 | 0.67 | 0.72 | 0.22 | 0.42 | 0.84 | 1.16 | 1.38 | 1.53 | 1.67 | 0.21 | 1.03 | 1.48 |
| — | -20.9% | -38.1% | -83.8% | -72.6% | -49.4% | +448.0% | +34.6% | +3.2% | -16.8% | -92.0% | -70.7% | -65.5% | |
| Interest Coverage | -26.53 | -42.40 | -27.61 | -29.40 | -40.29 | -29.39 | -19.82 | -43.69 | -7.02 | -12.41 | -19.40 | — | -4.82 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying NAOV stock.
NanoVibronix, Inc.'s current P/E is -0.1x. The average P/E over the last 1 quarters is 1.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
NanoVibronix, Inc.'s current operating margin is -140.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking NanoVibronix, Inc.'s business trajectory between earnings reports.